摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2,3-二甲氧基苯基)-4-哌啶基甲酮三氟乙酸盐 | 139290-73-6

中文名称
(2,3-二甲氧基苯基)-4-哌啶基甲酮三氟乙酸盐
中文别名
——
英文名称
4-(2,3-dimethoxyphenyl)-4-piperidinylmethanone trifluoroacetate
英文别名
(2,3-Dimethoxyphenyl)-4-piperidinylmethanone trifluoroacetate;(2,3-dimethoxyphenyl)-piperidin-4-ylmethanone;2,2,2-trifluoroacetic acid
(2,3-二甲氧基苯基)-4-哌啶基甲酮三氟乙酸盐化学式
CAS
139290-73-6
化学式
C2HF3O2*C14H19NO3
mdl
——
分子量
363.334
InChiKey
NYTCADZFPZZWEW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    二甲基甲酰胺、二甲基亚砜

计算性质

  • 辛醇/水分配系数(LogP):
    2.52
  • 重原子数:
    25
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    84.9
  • 氢给体数:
    2
  • 氢受体数:
    9

反应信息

点击查看最新优质反应信息

文献信息

  • DEUTERATED FORMS AND DERIVATIVES OF VOLINANSERIN
    申请人:Concert Pharmaceuticals Inc.
    公开号:EP3897507A1
    公开(公告)日:2021-10-27
  • Deuterated Forms And Derivatives Of Volinanserin
    申请人:Terran Biosciences, Inc.
    公开号:US20220106272A1
    公开(公告)日:2022-04-07
    Deuterated forms of volinanserin according to structural formula (I), and their pharmaceutically acceptable salts, pharmaceutical compositions containing these compounds, and methods of treatment or prevention using these compounds or pharmaceutical compositions are described. The compounds are useful for treating or preventing a disease or condition selected from psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, Lewy body dementia, sleep disorder (including insomnia), agitation, mood disorder (including depression), thromboembolic disorder, autism, and attention deficit hyperactivity disorder.
  • [EN] DEUTERATED FORMS AND DERIVATIVES OF VOLINANSERIN<br/>[FR] FORMES DEUTÉRÉES ET DÉRIVÉS DE VOLINANSÉRINE
    申请人:CONCERT PHARMACEUTICALS INC
    公开号:WO2020132461A1
    公开(公告)日:2020-06-25
    Deuterated forms of volinanserin according to structural formula (I), and their pharmaceutically acceptable salts, pharmaceutical compositions containing these compounds, and methods of treatment or prevention using these compounds or pharmaceutical compositions are described. The compounds are useful for treating or preventing a disease or condition selected from psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, Lewy body dementia, sleep disorder (including insomnia), agitation, mood disorder (including depression), thromboembolic disorder, autism, and attention deficit hyperactivity disorder.
  • WO2020132461A5
    申请人:——
    公开号:WO2020132461A5
    公开(公告)日:2022-10-21
  • COMBINATION OF A HYPNOTIC AGENT AND R (+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF
    申请人:EMMONS Gary T.
    公开号:US20080139615A1
    公开(公告)日:2008-06-12
    The invention concerns the combination of a short-acting hypnotic agent and R-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol (Compound A) or its prodrug having the Formula II: wherein R is C 1 -C 20 alkyl or a pharmaceutically acceptable salt thereof. The combination of this invention is useful in treating a variety of sleep disorders.
    该发明涉及短效催眠药剂和R-(+)-α-(2,3-二甲氧基苯基)-1-[2-(4-氟苯基)乙基]-4-哌啶甲醇(化合物A)或其具有II式的前药:其中R为C1-C20烷基或其药用可接受的盐。该发明的组合物在治疗各种睡眠障碍方面是有用的。
查看更多